JP7391019B2 - レノックス・ガストー症候群に関連した発作の治療におけるカンナビノイドの使用 - Google Patents

レノックス・ガストー症候群に関連した発作の治療におけるカンナビノイドの使用 Download PDF

Info

Publication number
JP7391019B2
JP7391019B2 JP2020526576A JP2020526576A JP7391019B2 JP 7391019 B2 JP7391019 B2 JP 7391019B2 JP 2020526576 A JP2020526576 A JP 2020526576A JP 2020526576 A JP2020526576 A JP 2020526576A JP 7391019 B2 JP7391019 B2 JP 7391019B2
Authority
JP
Japan
Prior art keywords
seizures
treatment
cbd
patients
epilepsy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020526576A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021502992A (ja
Inventor
ジェフリー・ガイ
フォルカー・ナッパーツ
Original Assignee
ジーダブリュー・リサーチ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60788456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7391019(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ジーダブリュー・リサーチ・リミテッド filed Critical ジーダブリュー・リサーチ・リミテッド
Publication of JP2021502992A publication Critical patent/JP2021502992A/ja
Priority to JP2023170155A priority Critical patent/JP7723711B2/ja
Application granted granted Critical
Publication of JP7391019B2 publication Critical patent/JP7391019B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2020526576A 2017-11-15 2018-11-15 レノックス・ガストー症候群に関連した発作の治療におけるカンナビノイドの使用 Active JP7391019B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023170155A JP7723711B2 (ja) 2017-11-15 2023-09-29 レノックス・ガストー症候群に関連した発作の治療におけるカンナビノイドの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1718862.4 2017-11-15
GB1718862.4A GB2568471B (en) 2017-11-15 2017-11-15 Use of cannabinoids in the treatment of epilepsy
PCT/GB2018/053315 WO2019097238A1 (en) 2017-11-15 2018-11-15 Use of cannabinoids in the treatment of seizures associated with lennox-gastaut syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023170155A Division JP7723711B2 (ja) 2017-11-15 2023-09-29 レノックス・ガストー症候群に関連した発作の治療におけるカンナビノイドの使用

Publications (2)

Publication Number Publication Date
JP2021502992A JP2021502992A (ja) 2021-02-04
JP7391019B2 true JP7391019B2 (ja) 2023-12-04

Family

ID=60788456

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020526576A Active JP7391019B2 (ja) 2017-11-15 2018-11-15 レノックス・ガストー症候群に関連した発作の治療におけるカンナビノイドの使用
JP2023170155A Active JP7723711B2 (ja) 2017-11-15 2023-09-29 レノックス・ガストー症候群に関連した発作の治療におけるカンナビノイドの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023170155A Active JP7723711B2 (ja) 2017-11-15 2023-09-29 レノックス・ガストー症候群に関連した発作の治療におけるカンナビノイドの使用

Country Status (16)

Country Link
US (1) US20210169824A1 (enExample)
EP (2) EP4487860A3 (enExample)
JP (2) JP7391019B2 (enExample)
KR (1) KR102786614B1 (enExample)
CN (1) CN111629756A (enExample)
AU (2) AU2018366443A1 (enExample)
BR (1) BR112020009508A2 (enExample)
CA (1) CA3082433A1 (enExample)
DK (1) DK3710058T3 (enExample)
ES (1) ES2991947T3 (enExample)
FI (1) FI3710058T3 (enExample)
GB (1) GB2568471B (enExample)
IL (1) IL274633A (enExample)
MX (2) MX2020005147A (enExample)
RU (1) RU2020119390A (enExample)
WO (1) WO2019097238A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
GB201910389D0 (en) 2019-07-19 2019-09-04 Gw Pharma Ltd Novel compounds, methods for their manufacture, and uses thereof
GB2588576A (en) 2019-08-27 2021-05-05 Gw Res Ltd Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease
GB201916846D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916849D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916977D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannibidol-type cannabinoid compound
GB201916974D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannabidol-type cannabinoid compound
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
GB202009321D0 (en) 2020-06-18 2020-08-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
KR102891881B1 (ko) 2020-07-16 2025-11-26 주식회사 엘지에너지솔루션 듀얼 슬롯 다이 코터
GB2597304A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with shaken baby syndrome
WO2022017936A1 (en) * 2020-07-20 2022-01-27 GW Research Limited Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597280A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with auriculotemporal syndrome
GB202013765D0 (en) 2020-09-02 2020-10-14 Gw Res Ltd Method of preparing cannabinoids
EP4412619A4 (en) * 2021-10-04 2025-11-12 Marinus Pharmaceuticals Inc GANAXOLONE FOR THE TREATMENT OF BOURNEVILLE'S TUBEROUS SCLEROSIS AND EPILEPTIC DISORDERS
US12036228B2 (en) 2022-04-12 2024-07-16 Shackelford Pharma Inc. Treatment of seizure disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016203239A1 (en) 2015-06-17 2016-12-22 GW Research Limited Use of cannabinoids in the treatment of epilepsy
JP2017519758A (ja) 2014-06-17 2017-07-20 ジーダブリュー・ファーマ・リミテッドＧｗ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ てんかんの治療におけるカンナビジオールの使用
JP2017519742A (ja) 2014-05-29 2017-07-20 インシス・ファーマ・インコーポレーテッド 安定なカンナビノイド製剤
JP2017531667A (ja) 2014-10-14 2017-10-26 ジーダブリュー・ファーマ・リミテッドＧｗ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ 癲癇の治療におけるカンナビノイドの使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170224634A1 (en) * 2014-05-29 2017-08-10 Insys Development Company, Inc. Stable cannabinoid formulations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017519742A (ja) 2014-05-29 2017-07-20 インシス・ファーマ・インコーポレーテッド 安定なカンナビノイド製剤
JP2017519758A (ja) 2014-06-17 2017-07-20 ジーダブリュー・ファーマ・リミテッドＧｗ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ てんかんの治療におけるカンナビジオールの使用
JP2017531667A (ja) 2014-10-14 2017-10-26 ジーダブリュー・ファーマ・リミテッドＧｗ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ 癲癇の治療におけるカンナビノイドの使用
WO2016203239A1 (en) 2015-06-17 2016-12-22 GW Research Limited Use of cannabinoids in the treatment of epilepsy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Anuals of neurology，2017年，82，s293
Child Neurology Foundation H，2016年06月27日，https://www.childrenneurologyfoundation.org/gw-pharmaceuticals-announces-positive-phase-3-pivotal-trial-results-epidiolex-cannabidiol-treatment-lennox-gastaut-syndrome/
Lancet Neulorogy，2016年，15，270-278
Neurology Advisor，2017年04月26日，p1-3

Also Published As

Publication number Publication date
RU2020119390A (ru) 2021-12-15
JP2021502992A (ja) 2021-02-04
KR20200088356A (ko) 2020-07-22
CA3082433A1 (en) 2020-05-15
EP4487860A3 (en) 2025-04-02
WO2019097238A1 (en) 2019-05-23
AU2018366443A1 (en) 2020-06-11
RU2020119390A3 (enExample) 2021-12-15
US20210169824A1 (en) 2021-06-10
CN111629756A (zh) 2020-09-04
EP3710058B1 (en) 2024-10-09
ES2991947T3 (es) 2024-12-05
MX2023012352A (es) 2023-10-31
AU2024216397A1 (en) 2024-09-19
KR102786614B1 (ko) 2025-03-26
GB2568471A (en) 2019-05-22
GB2568471B (en) 2022-04-13
JP7723711B2 (ja) 2025-08-14
BR112020009508A2 (pt) 2020-10-13
JP2023168448A (ja) 2023-11-24
DK3710058T3 (da) 2024-11-04
EP4487860A2 (en) 2025-01-08
FI3710058T3 (fi) 2024-11-11
EP3710058A1 (en) 2020-09-23
NZ764569A (en) 2024-11-29
MX2020005147A (es) 2020-08-20
IL274633A (en) 2020-06-30
GB201718862D0 (en) 2017-12-27

Similar Documents

Publication Publication Date Title
JP7391019B2 (ja) レノックス・ガストー症候群に関連した発作の治療におけるカンナビノイドの使用
AU2023258400B2 (en) Use of cannabinoids in the treatment of epilepsy
US20220202738A1 (en) Cannabinoids in the treatment of epilepsy
US11400055B2 (en) Use of cannabidiol in the treatment of epilepsy
JP7712079B2 (ja) てんかんの処置におけるカンナビノイドの使用
JP7256186B2 (ja) てんかんの治療におけるカンナビノイドの使用
WO2017168138A1 (en) Use of cannabinoids in the treatment of sturge weber syndrome
EP3310390A1 (en) Use of cannabinoids in the treatment of epilepsy
TW202108133A (zh) 大麻二酚於治療結節性硬化症之用途
CN116887819A (zh) 大麻二酚和氯巴占在儿童期发病癫痫综合征治疗中的用途
HK40040845A (en) Use of cannabinoids in the treatment of epilepsy
HK40040845B (en) Use of cannabinoids in the treatment of epilepsy

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211001

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230220

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230929

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231006

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231030

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231121

R150 Certificate of patent or registration of utility model

Ref document number: 7391019

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350